ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors

NCT05276609 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: HS-20093 (Phase Ia: Dose escalation)
DRUG: HS-20093 (Phase Ib: Dose expansion)

Sponsor

Shanghai Hansoh Biomedical Co., Ltd